Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.66 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glemanserin SCHEMBL7838106 | 0.98 | HTR2A (0.97) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9328976 | 0.92 | HTR2A (0.84) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL6057184 | 0.91 | HTR2A (0.84) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9329004 | 0.90 | HTR2A (0.82) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9328969 | 0.90 | HTR2A (0.82) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9328582 | 0.90 | HTR2A (0.87) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9330147 | 0.90 | HTR2A (0.87) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL9179569 | 0.90 | HTR2A (0.82) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL10340052 | 0.90 | HRH1 (0.84) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 | |
| SCHEMBL7375182 | 0.90 | HTR2A (0.83) | HTR2AHTR2CKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | TERRAN BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250129054-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY-N-METHCATHINONE AND USES THEREOF | TERRAN BIOSCIENCES INC (US) | 2025-04-24 | — | — | US | claimed |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | TERRAN BIOSCIENCES INC. | 2025-04-24 | — | — | US | claimed |
| US-20250109130-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | TERRAN BIOSCIENCES INC (US) | 2025-04-03 | — | — | US | claimed |
| US-20250091993-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | TERRAN BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | claimed |
| EP-0325063-B1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMA (US) | 1994-03-09 | — | — | EP | claimed |
| US-5169096-A | Serotonin antagonists, analgesics | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-12-08 | — | — | US | claimed |
| US-5106855-A | Method for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-21 | — | — | US | claimed |
| US-5021428-A | Novel chemical compounds for the prophylactic treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-06-04 | — | — | US | claimed |
| US-4912117-A | Therapy for varient angina | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-27 | — | — | US | claimed |
| US-4908369-A | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | claimed |
| US-4877798-A | Treatment of fibromyalgia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-31 | — | — | US | claimed |
| EP-0337136-A2 | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0319962-A2 | Piperidinyl methanol derivatives for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-14 | — | — | EP | claimed |
| EP-0317933-A2 | Treatment of fibromyalgia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-05-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129054-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY-N-METHCATHINONE AND USES THEREOF | CYP2C19, CYP11B1, CYP2D6 | HTR2A 973/4885HTR2C 433/4885KDM4E 747/4885 |
| US-20250091993-A1 | SALTS AND SOLID FORMS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | SLC1A2, SLC6A4, SLC6A3 | HTR2A 48/4885HTR2C 44/4885KDM4E 468/4885 |
| US-20260000641-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (IMDAI) | DRD2, HTR1D, DRD1 | HTR2A 7/4885HTR2C 4/4885KDM4E 243/4885 |
| US-20250109130-A1 | ISOTOPICALLY ENRICHED ANALOGS OF 2-BROMO-LSD, LSD, ALD-52, AND 1P-LSD | LMNB2, CLN6, EPM2A | HTR2A 10/4885HTR2C 32/4885KDM4E 984/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2A 1/4885HTR2C 5/4885KDM4E 4347/4885 |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | HTR2A 2/4885HTR2C 6/4885KDM4E 1420/4885 |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | SLC6A4, SLC6A3, SLC6A2 | HTR2A 91/4885HTR2C 60/4885KDM4E 1186/4885 |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | GBA2, GBA1, SLC18A2 | HTR2A 9/4885HTR2C 16/4885KDM4E 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.